Literature DB >> 12171815

Cerebral oxygenation during exercise in patients with terminal lung disease.

Gabrielle Jensen1, Henning Bay Nielsen, Kojiro Ide, Per Lav Madsen, Lars Bo Svendsen, Ulrik Gerner Svendsen, Niels Henry Secher.   

Abstract

STUDY
OBJECTIVES: In patients with terminal lung disease who were exercising, we assessed whether improved arterial O2 saturation with an increased fraction of inspired oxygen (FIO2) affects cerebral oxygenation.
DESIGN: Randomized, crossover. PATIENTS AND METHODS: The cerebral changes in oxyhemoglobin (DeltaHbO2) and changes in deoxyhemoglobin (DeltaHb) levels were evaluated using near-infrared spectrophotometry and the middle cerebral artery (MCA) mean velocity (V(mean)) was determined by transcranial Doppler ultrasonography in 13 patients with terminal lung disease (New York Heart Association class III-IV). Patients were allocated to an FIO2 of either 0.21 or 0.35 during incremental exercise with 15 min between trials.
RESULTS: Peak exercise intensity (mean [+/- SE], 26 +/- 4 W) reduced the arterial O2 pressure (at rest, 64 +/- 3 mm Hg; during exercise, 56 +/- 3 mm Hg) and the arterial oxygen saturation (SaO2) [at rest, 92 +/- 2%; 87 +/- 2%; p < 0.05], while the arterial CO2 pressure was not significantly affected. The MCA V(mean) increased from 49 +/- 5 to 63 +/- 7 cm/s (p < 0.05) as did the DeltaHb, while the DeltaHbO2 remained unaffected by exercise. With an elevated FIO2, the SaO2 level (at rest, 95.8 +/- 0.7%; during exercise, 96.0 +/- 1.0%) and arterial O2 pressure (at rest, 102 +/- 11 mm Hg; during exercise, 100 +/- 8 mm Hg) were not significantly affected by exercise, and the levels of blood oxygenation remained higher than the values established at normoxia (p < 0.05). The MCA V(mean) increased to a level similar to that achieved during control exercise (ie, to 70 +/- 11 cm/s). In contrast to control exercise, DeltaHb decreased while DeltaHbO2 increased during exercise with 35% O2 (p < 0.05).
CONCLUSION: An O2-enriched atmosphere enabled patients with terminal lung disease to maintain arterial O2 saturation during exercise. An exercise-induced increase in cerebral perfusion was not affected by hyperoxia, whereby the enhanced availability of oxygenated hemoglobin increases cerebral oxygenation. The clinical implication of the study is that during physical activity patients with terminal lung disease are recommended to use an elevated FIO2 to protect cerebral oxygenation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171815     DOI: 10.1378/chest.122.2.445

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Gait capacity affects cortical activation patterns related to speed control in the elderly.

Authors:  Taeko Harada; Ichiro Miyai; Mitsuo Suzuki; Kisou Kubota
Journal:  Exp Brain Res       Date:  2008-11-22       Impact factor: 1.972

2.  Effects of exercise and vasodilators on cerebral tissue oxygenation in pulmonary hypertension.

Authors:  Séverine Müller-Mottet; Florian F Hildenbrand; Stephan Keusch; Elisabeth Hasler; Marco Maggiorini; Rudolf Speich; Konrad E Bloch; Silvia Ulrich
Journal:  Lung       Date:  2014-11-21       Impact factor: 2.584

3.  Frontal cerebral cortex blood flow, oxygen delivery and oxygenation during normoxic and hypoxic exercise in athletes.

Authors:  Ioannis Vogiatzis; Zafeiris Louvaris; Helmut Habazettl; Dimitris Athanasopoulos; Vasilis Andrianopoulos; Evgenia Cherouveim; Harrieth Wagner; Charis Roussos; Peter D Wagner; Spyros Zakynthinos
Journal:  J Physiol       Date:  2011-07-04       Impact factor: 5.182

Review 4.  Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial.

Authors:  James K Stoller; Ralph J Panos; Samuel Krachman; Dennis E Doherty; Barry Make
Journal:  Chest       Date:  2010-07       Impact factor: 9.410

5.  Cerebrovascular responses to submaximal exercise in women with COPD.

Authors:  Sara E Hartmann; Richard Leigh; Marc J Poulin
Journal:  BMC Pulm Med       Date:  2014-06-05       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.